CS MEDICA A/S approved for listing at Spotlight Stock Market
CS MEDICA A/S (the “Company” or “CS MEDICA”) is a Danish-based medico growth company exploring and harnessing the potential of substances in the Cannabis sativa L. plant. The Company operates within pain relief and caretaking across the nations of Europe. The Company was founded in 2011 and has its headquarters in Copenhagen, Denmark.
CS MEDICA A/S, registered in 2011, is a Danish medico company committed to developing and commercializing evidence-based and innovative medical devices, containing cannabinoids from cannabis, within pain relief and care taking.
CS MEDICA is exploring and harnessing the potential prosperities of the substances in the Cannabis sativa L. plant. The Company’s vision is to become a world-leading manufacturer of medical devices containing cannabinoids from cannabis. The Company’s ambition is to continuously develop safe and effective products with the ability to increase the life quality for patients and people in general. The Company’s mission is to harness medical cannabis to increase the understanding of the biology that controls the endocannabinoid system. The Company will use that knowledge to develop and sell products that enable people to live with less pain and increase life quality.
"We are happy to be approved for listing on Spotlight Stock Market. Our vision as a public company is to improve the wide public's life quality by offering effective and safe treatment solutions. We aim to be in constant development, exploring how CS MEDICA can support patients in their battle against disease, pain, and the sorrow it brings. The listing and forthcoming IPO are important steps for CS MEDICA as we continue with our work to reach our targets for the operation, primarily focusing on advancing across the European market, and continuing our research, and development activities. Moving ahead, we want to further our advancements working with carefully selected partners to establish our CANNASEN® product lines across European borders.”
- CEO Lone Henriksen, CS MEDICA A/S
CS MEDICA A/S is planning to use the proceeds from the initial issue to increase market penetration, advance research and development (R&D) activities and conduct clinical trials in accordance with MDR. The Company will also update all systems from MDD to MDR, finalize portals, initiate, and finalize FDA application, and market analyses (the US and Canada), initiate patent applications for the upcoming treatment products and securing the Company’s IPR across the globe. The Company is therefore conducting an issue of units (shares and free of charge warrants) amounting to approx. DKK 33.1 million (before issue costs of approx. DDK 1.8 million), prior to planned listing on Spotlight Stock Market.
The Offer
The offer comprises no more than 2,902,000 shares and no more than 1,160,800 warrants of series TO 1, corresponding to approx. DKK 22.3 million and approx. DKK 10.8 million respectively. If the issue of units is fully subscribed and all associated warrants are exercised, CS MEDICA will receive a capital injection totaling approx. DKK 33.1 million (before issue costs). The minimum subscription is 120 units, corresponding to DKK 4,620. The subscription period starts on the 17th of August 2021, and ends on the 31st of August 2021. The valuation (pre-money) amounts to approximately DKK 61.6 million.
Subscription period: 17th of August – 31st of August 2021.
Expected first day of trading on Spotlight Stock Market: 14th of September 2021.
Subscription price: DKK 38.50 per unit. One (1) unit consists of five (5) new shares and two (2) warrants of series TO 1, free of payment.
Valuation (pre-money): Approx. DKK 61.6 million.
Subscription commitments: The Company has received subscription commitments of approximately DKK 13.4 million, corresponding to approximately 60 percent of the initial issue of units.
Listing at Spotlight Stock Market
CS MEDICA A/S has been approved for listing at Spotlight Stock Market. The first day of trading is planned for the 14th of September 2021. The approval is given under the condition that the company raises the lowest level of approximately DKK 26.7 million and that the company obtains a sufficient number of shareholders in accordance with Spotlight Stock Market’s listing agreement in the upcoming IPO.
Information about the share
Short name: CSMED
ISIN: DK0061668225
Expected first day of trading: 14th of September 2021
Information about the warrants
Short name: CSMED TO 1
ISIN: DK0061668308
Subscription period for the warrants: 18th of August – 1st of September, 2022
The companys prospectus will be published at www.spotlightstockmarket.com after the approval of The Danish Financial Supervisory Authority.
For more information, please contact:
Carl-Henrik Nordberg
Head of Listing, Spotlight Stock Market
+46 8 511 68 008
listing@spotlightstockmarket.com